Adding cyclooxygenase inhibitors to immune checkpoint inhibitors did not improve outcomes in metastatic renalcell carcinoma

HIGHLIGHTS

• who: Yumeng Zhang et al. from the Division of Hematology and Medical Oncology, HLee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA have published the paper: Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic RenalCell Carcinoma, in the Journal: Cells 2022, 11, 2505. of 10/08/2022
• what: The study demonstrated that combining COXis with ICIs did not result in longer disease control nor improved survival outcomes among patients with mRCC.
• how: The authors conducted a retrospective cohort study to determine whether concurrently using COX inhibitors . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.